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Abstract
Background. Monitoring changes in glomerular filtration
rate (GFR) is the recommended method for assessing the
progression of kidney disease. The aim of this study was to
assess the decline of graft function defined by the annual-
ized change in GFR and the factors which affect it.
Methods. Four thousand four hundred and eighty-eight
patients, transplanted during the years 1990, 1994, 1998
and 2002 in 34 centres in Spain with allograft survival
of at least 1year, were included in the study. GFR was es-
timated using the four-variable equation of the Modifica-
tion of Diet in Renal Diseases (MDRD) study. Linear
mixed effects model was applied to determine the relation
between the covariates and the annualized change in GFR
after transplantation.
Results. The average GFR at 12 months was 51.4 ±
18.9 mL/min/1.73 m
2; most patients were in stage 3 of
chronic kidney disease classification. The average patient
slope, calculated in a linear model with varying-intercept
and varying-slope without covariates, was −1.12 ±
0.05 mL/min/year (slope ± standard error). Some variables
were related to both the 12-month GFR (intercept) and the
slope: recipient gender, hepatitis C virus (HCV) status, es-
timated GFR (eGFR) at 3 months and proteinuria at
12 months. Some variables were only related to the slope
of eGFR: time on dialysis, primary renal disease and im-
munosuppression. Others affected only the 12-month
GFR: donor age, delayed graft function, acute rejection
and systolic blood pressure at 12 months. Higher graft
function at 3 months had a negative impact on the GFR
slope. Cyclosporine-based immunosuppression had a less
favourableeffectontheratesofchangeinallograftfunction.
Conclusions. There was a slow decline in GFR. Poor graft
functionwasnotassociatedwithanincreasedrateofdecline
of allograft function. Immunosuppression with cyclospor-
ine displayed the worst declining GFR rate.
Keywords: glomerular filtration rate; immunosuppression; kidney
transplantation
Introduction
The new immunosuppressive drugs have decreased the in-
cidence of rejection and have improved short-term graft
survival. However, there has been little or no improvement
in late allograft failure [1,2]. The lack of long-term im-
provement in graft outcomes has been attributed to the in-
creased mortality of recipients with functioning grafts,
mostly by cardiovascular diseases, and to graft losses by
chronic allograft nephropathy, 50% of losses being due
to patient death and the remainder to loss of function
[3]. On the other hand, it has been reported that graft func-
tion measured by serum creatinine early after transplanta-
tion was an important predictive factor of graft survival
[4]. Consequently, improving and maintaining early graft
function could reduce the rate of late graft failure. How-
ever, serum creatinine is not an accurate index of graft
function. The Kidney Disease Outcome Quality Initiative
(K/DOQI) [5] guidelines have recommended measuring
graft function in primary renal diseases by estimated cre-
atinine clearance (eCrCl) or glomerular filtration rate
(eGFR) including variables such as age, sex and race.
Monitoring changes in GFR has been established as the
recommended method for assessing the progression of
kidney disease (K/DOQI).
Asinmostnativekidneydiseases,GFRdeclines progres-
sively over time in renal transplant recipients. Several stud-
ies from the USA and Canada have shown that the decline
of renal function can be calculated post-transplantation
from the slope of eCrCl or eGFR beyond 6 or 12 months
after transplantation [6–12]. But, in most of these studies,
the decline of graft function was calculated by linear least
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two measurements. However, there are other statistical
methods to estimate the decline of graft function. For exam-
ple, the measurement of progression of renal disease in the
Modification of Diet in Renal Disease Study (MDRD) was
estimated using linear mixed effects models [13].
The purpose of the present study was to evaluate, in a
large Spanish population of renal transplant recipients, the
rate of decline of graft function after transplantation and
the factors associated with this change, making special em-
phasis on baseline graft function and immunosuppression
using the linear mixed effects model.
Materials and methods
Patients
From a total of 4842 adult renal transplant recipients from 34 centres re-
ceiving a renal allograft in Spain during the years 1990, 1994, 1998 and
2002, 4488 were included in the study. The inclusion criteria were to be
recipients of a single organ, with the graft functioning 12 months after
transplantation and >2 years of follow-up. Patients were followed up until
graft loss, death or December 2005, whichever occurred before. The mean
follow-up was 74.0 ± 43.9 months. Altogether, 26 667 reviews were per-
formed, corresponding to a mean of six reviews per patient.
Methods
Data concerned recipients (age, gender, primary renal disease, time on
dialysis, type of dialysis, height and weight, serology to hepatitis C and
B virus and last panel-reactive antibodies), donors (age, gender, type of
donor, cause of donor death and serology to hepatitis C and B virus),
grafts [human leucocyte antigen (HLA) mismatches, warm and cold is-
chaemia times, re-anastomosis time, immediate graft function, rejection
episodes and immunosuppression]. Clinical and biochemical variables
(haemoglobin, serum creatinine, proteinuria, blood glucose, serum lipids)
were collected at 3 months, 12 months and yearly until the end of the
follow-up.
Delayed graft function was defined by haemodialysis requirement dur-
ing the first week. Acute rejection was defined at each centre based on
clinical and/or histological data. Immunosuppressive treatment was re-
corded at each visit and classified into three groups: (i) cyclosporine-
based, (ii) tacrolimus-based and (iii) calcineurin inhibitor (CNI)-free
therapy. The CrCl was estimated by the Cockcroft–Gault equation: CrCl
(mL/min) = [(140 − age) × weight] / [72 × SCr (mg/dL)] × (0.85 if
female). The estimated GFR (eGFR) was estimated using the abbreviated
MDRD equation: eGFR (mL/min/1.73 m
2) = exp(5.228 − 1.154) × ln
(SCr) − 0.203 × ln(age) − (0.299 if female) + (0.192 if black). The study
was approved by the ethical committee of the Hospital de Bellvitge.
Medical record review was performed according to Spanish law with ref-
erence to clinical data confidentiality protection. A blinded code was as-
signed to each participating hospital in order to take into consideration
centre effect.
Statistics
Patient characteristics were described as mean and standard deviation for
continuous variables and frequency for categorical variables. All available
creatinine measurements recorded were included in the serial GFR esti-
mates. Progression of chronic kidney disease (CKD) was analysed by the
mixed effects model:
GFRi=β0+β1  year +a  Xi+b  Xi  year +ei
where i = 1, 2,..., 4488. GFRi is the GFR for the ith patient, β coeffi-
cients correspond to the random effects, which allow the intercept and
the slope to be different for each patient, a and b are the vector of fixed
effects, X is a vector of the covariates, and ei is a vector of residuals
[14,15]. In order to take into account the correlation between successive
patient measures, we considered a model with first-order autoregressive
structure for the residuals. The coefficient of interaction terms, b Xi
year, measures the influence of these covariates in the change of the
slope according to the estimated model. The time origin (year = 0)
was fixed at 12 months.
The covariates included in the model were: (i) Recipient: age, gender,
primary renal disease, time on dialysis, hepatitis C virus (HCV) serol-
ogy; (ii) Donor and graft: age, gender, type of donor, number of trans-
plants, cold ischaemia time, delayed graft function, acute rejection, year
of transplantation and graft function at 3 months; (iii) Characteristics at
12 months: blood pressure, body mass index (BMI), proteinuria, immu-
nosuppression and graft function estimated as chronic kidney disease
stages. For calculations, time on dialysis and proteinuria were converted
to natural logarithms. Univariate and multivariate analysis were per-
formed. We explored a multivariate model, which included all clinical
relevant variables, and selected a final model retaining as many vari-
ables as possible using de AKAIKE Information Criterion (AIC). We
estimated the slope in the multivariate analysis by two models: in the
first, only the available eGFR were used; in the second, we imputed a
GFR of 10 mL/min/1.73 m
2 to patients who returned to dialysis at the
date of graft failure.
Results
Characteristics of the patients
The patient characteristics are contained in Table 1; some
data are missing, and the number of patients did not reach
4488. There was a progressive increase of recipient age
from 42.5 ± 12.2 years in 1990 to 48.3 ± 13.3 years in
2002 (P = 0.000). Donor age also increased from 32.7 ±
14.6 in 1990 to 46.4 ± 16.4 in 2002 (P = 0.000). Time on
dialysis decreased from 3.8 ± 3.4 years in 1990 to 3.1 ±
3.8 years in 2002 (P = 0.000) as well as cold ischaemia
time from 20.8 ± 6.6 h in 1990 to 18.1 ± 6.0 in 2002
(P = 0.000). Most patients were on haemodialysis, and
they received a kidney from a deceased donor. Immuno-
suppression at 12 months was cyclosporine-based in
70.4% and tacrolimus-based in 23.2%, and only 6.4%
of patients were in CNI-free immunosuppression. During
the follow-up, 842 recipients lost their grafts. The causes
of graft loss were: death with graft function (36.0%), bi-
opsy-confirmed chronic allograft nephropathy (22.2%),
chronic allograft nephropathy without histological confir-
mation (27.4%), recurrent glomerulonephritis (3.3%), de
novo glomerulonephritis (2.9%) and others (8.2%).
Graft function
At 12 months, the mean serum creatinine of the 4488 pa-
tients was 1.6 ± 1.5 mg/dL, median (range 0.5–6.7 mg/dL).
Themeancreatinineclearance(n=4079)determinedbythe
Cockroft–Gault equation was 60.7 ± 21.8 mL/min, median
58.5 mL/min (range 11–162 mL/min), and the mean eGFR
calculated by the MDRD study equation was 51.7 ±
18.8 mL/min/1.73 m
2, median 49.02 mL/min/1.73 m
2
(range 7.9–139 mL/min/1.73 m
2). Proteinuria at 12 months
measured as gram per 24 h was available in 4288 recipients.
The distribution of CKD stages at 12 months for stages 1–5
was 2.7%, 27.1%, 59.4%, 10.3% and 0.5% according to
eGFR. Avery similar CKD stage distribution was observed
at 5 and 10 years (Figure 1).
CKD progression
The eGFR rate declined from 12 months to last visit, with a
mean of −1.26 ± 6.24 mL/min/year (mean ± standard devi-
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39.1 mL/min/year)when we determined the slope byapply-
ing the least squares regression for each patient. If we used
the linear mixed effects models, varying intercept and slope
for each patient, the decline was −1.12 ± 0.05 mL/min/
1.73 m
2 per year (coefficient ± standard error) (Figure 2).
In the mixed effects model, we have used all the baseline
characteristics described in Table 1 to analyse the evolution
of eGFR along the time offollow-up. In the univariate anal-
ysis, the variables correlated with GFR at 12 months (inter-
cept) were: recipient age and sex, donor age and sex, HLA
mismatches, delayed graft function, acute rejection, GFR at
3 months, immunosuppression, BMI, proteinuria, blood
pressure and serum lipids at 12 months. Table 1 shows
the coefficient and the standard error of covariates associat-
ed with the GFR slope. The coefficients represent the inter-
action (covariate × time). For continuous variables, the
coefficient is the mean of the change in GFR decline for
each unit change in the predictor variablewhilemaintaining
the other covariates fixed in the model. For example, mean
GFR decline was 0.020 ± 0.004 mL/min/1.73 m
2 per year
faster for each year of age. For binary variables such as re-
cipient and donor sex, type of donor, delayed graft function
and acute rejection at 12 months, the coefficient is the mean
difference in GFR decline between the two groups. For ex-
ample, mean GFR decline was 0.358 ± 0.100 mL/min/year
faster in female than in male recipients. For variables with
more than two categories, such as primary renal disease and
treatmentgroup,havingkpossibilities orcategorieswithout
a definite order, we constructed a series of k-1 binary dum-
my variables, coding one as reference. The coefficient for
the other categories is the mean difference in GFR decline
between this category and the reference. Diabetes mellitus
was the reference in primary renal disease variable and cy-
closporine in the immunosuppressive treatment. For exam-
ple, mean GFR decline was 1.135 ± 0.332 mL/min/year
slower in CNI-free-treated recipients than in cyclosporine-
treated recipients.
In the univariate analysis, among the baseline character-
istics of the patients, age at transplant, sex, time on dialy-
Table 1. Characteristics of the patients and CKD progression (univariate analysis)
Variable Mean ± SD or % Coefficient ± SE t
Age at transplant (years) 45.9 ± 13.1 0.020 ± 0.004 5.24
Gender (male/female) 2819/1669 −0.358 ± 0.100 −3.52
Time on dialysis (years) 3.3 ± 3.7 −0.278 ± 0.048 −5.78
Type of dialysis (vs haemodialysis)
Haemodialysis 3842 (85.6%) 0.229 ± 0.179 1.28
Peritoneal dialysis 418 (9.6%) −0.088 ± 0.298 −0.30
Both 117 (2.7%)
HCV status (negative/positive) 3578/576 −0.766 ± 0.136 −5.63
Primary renal disease (vs diabetes)
Diabetes 237 (5.3%)
Chronic glomerulonephritis 1007 (22.5%) 0.784 ± 0.248 3.01
Interstitial nephritis 570 (12.7%) 0.604 ± 0.302 2.00
Nephroangiosclerosis 315 (7.0%) 0.680 ± 0.269 2.52
Polycystic disease 596 (13.3%) 1.017 ± 0.270 2.78
Unknown/other 1763 (39.3%) 0.738 ± 0.249 2.96
Donor age (years) 41.8 ± 16.9 0.002 ± 0.003 0.66
Donor gender (male/female) 2906/1582 0.059 ± 0.103 0.57
Cold ischaemia time (hours) 19.2 ± 7.1 0.009 ± 0.006 1.41
Type of donor (deceased/living) 4425/63 −0.864 ± 0.438 −1.97
HLA mismatches (n) 3.2 ± 2.5 −0.009 ± 0.041 −0.22
Number of transplant (first/re-transplant) 3950/538 −0.703 ± 0.154 −4.57
Delayed graft function (no/yes) 2952/1275 0.077 ± 0.112 0.69
Acute rejection (no/yes) 3204/1211 −0.159 ± 0.107 −1.50
Immunosuppression at 12 months (vs CsA)
Cyclosporine 3163 (70.5%)
Tacrolimus 1044 (23.3%) 0.382 ± 0.178 2.15
No calcineurin inhibitors 133 (2.9%) 1.135 ± 0.332 3.42
eGFR at 3 months (mL/min/1.73 m
2) 51.2 ± 20.0 −0.026 ± 0.002 −10.00
BMI at 12 months (kg/m
2) 26.4 ± 4.3 0.016 ± 0.016 1.02
Proteinuria at 12 months (g/24 h) 0.3 ± 0.8 −0.064 ± 0.125 −5.15
Systolic blood pressure at 12 months (mmHg) 139 ± 18 −0.002 ± 0.003 −0.68
Diastolic blood pressure at 12 months (mmHg) 81 ± 11 −0.001 ± 0.001 0.12
Total cholesterol at 12 months (mg/dL) 219 ± 46 0.001 ± 0.001 1.21
Triglycerides at 12 months (mg/dL) 148 ± 71 0.250 ± 0.125 2.01
CKD stage at 12 months (vs stage 5)
Stage 5 22 (0.49%)
Stage 4 459 (10.27%) −0.674 −0.76
Stage 3 2656 (59.44%) −1.057 −1.22
Stage 2 1210 (27.08%) −1.732 −1.99
Stage 1 121 (2.71%) −4.804 −5.26
The coefficient represents the interaction of the covariate and the time. The differences are statistically significant when t >2.HCV , hepatitis C virus;
CsA, cyclosporine; BMI, body mass index; CKD, chronic kidney disease.
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GFR slope. The number of transplants and re-transplanta-
tion was also associated with GFR slope. There was no as-
sociation with donor age, donor sex, type of donor, cold
ischaemia time, delayed graft function and acute rejection.
Concerning patient characteristics at 12 months, protein-
uria and immunosuppression were associated with GFR
slope, and there was no association with body mass index,
systolic and diastolic blood pressure, serum cholesterol le-
vels, triglycerides levels and graft function expressed as
CKD stages.
The variables significantly associated with GFR inter-
cept (value at 12 months after transplant) and slope in
the multivariate analysis are expressed in Table 2; the num-
ber of patients included in the final analysis was 3502.
Several variables: donor gender, HCV status, donor age,
delayed graft function, acute rejection, eGFR at 3 months,
proteinuria at 12 months and systolic blood pressure at
12 months had an impact on the 12-month eGFR. Some
variables affected both the 12-month eGFR and the subse-
quent slope: donor gender, HCV status, eGFR at 3 months
and proteinuria at 12 months. Other variables affected only
the slope of eGFR: time on dialysis, primary renal disease
and immunosuppression. There was a great variability in
inter- and intra-patient slope; the square root of the esti-
mated variance inter-patients was 1.5, and the square
root of the residual variance (intra-patients) was 9.4.
As expected, the estimated stationary autocorrelation was
moderately large (0.44), indicating a fair amount of auto-
correlation amongst the model residuals.
When we analysed a model in which we imputed a GFR
of 10 mL/min on the date of graft failure to the patients
who returned to dialysis, there were no significative
changes in the results. In order to explore a non-linear
change of GFR, we tested a model with a quadratic term
for the time, finding it not relevant.
Discussion
The distribution of CKD stages was similar to other studies
performed in Spain [16,17] and in other countries [18,19],
and most of the patients were in the 3T stage. Furthermore,
this distribution of CKD stages did not change with the
length of follow-up, and no significant differences were
observed at 1, 5 and 10 years after transplantation. We
have observed a very slow decline rate of graft function
(−1.12 ± mL/min per 1.73 m
2 per year), lower than that
previously reported from single-centre studies [6,10,11,
20] or from registries [7,8]. These differences could be
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Fig. 1. Distribution of chronic kidney disease stages at 1, 5 and 10 years.
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at transplant, graft function at starting the study and length
of follow-up were not different to those of our patients. An-
other possible explanation could be a better control of other
variables such as blood pressure, serum lipid levels or pro-
teinuria, and finally, the differences could also be explained
bythemethodusedtocalculatetheslope,mixedeffect anal-
ysis in our study and single regression in most previous
studies. A common finding in our and other studies when
analysing the decline in graft function over time was the
great inter-patient variability in the slope of GFR [9]. Pa-
tientswithslower progressionofgraftfunctiondeterioration
and patients with improvements suggest that the grafts still
retain a certain capacity of hypertrophy as is typical of
solitary native kidneys in response to uninephrectomy.
The multivariate analysis demonstrated that some vari-
ables were independently associated with the 12-month
eGFR such as recipient gender, HCV status, donor age, de-
layed graft function, acute rejection, eGFR at 3 months,
proteinuria and systolic blood pressure at 12 months. Do-
nor age and acute rejection were the factors with the stron-
gest association with the 12-month graft function. Several
of these variables were associated with 6-month Cock-
croft–Gault estimate of CrCl in other studies [6,7,20]. In
contrast, our data did not confirm any association of
HLA mismatches, panel-reactive antibodies type of donor
and 12-month graft function [6,7,20]. The influence of
HLA matching and panel-reactive antibodies in the evolu-
tion of graft function could support the importance of im-
munological factors in allograft function; a more potent
immunosuppression could explain our differences with
the other studies. Concerning the type of donor, the num-
ber of living donors was too small to establish robust com-
parisons with deceased donors.
When we analysed the variables associated with the
slope of eGFR, some variables (donor age, delayed graft
function and rejection) associated with graft function at
12 months did not affect the slope of eGFR, but the time
on dialysis, diabetes as primary renal disease and immuno-
suppression did. Graft function at 3 months, proteinuria,
recipient gender and time on dialysis were the variables
which showed the strongest association with the slope of
eGFR. The influence of initial graft function in the pro-
gression of graft failure has been investigated in several
previous works. Gill et al. [7] found, in 40 963 renal trans-
plant recipients, a small but significantly more rapid de-
cline in GFR in patients with a higher baseline GFR,
and their findings are supported by other single-centre
studies [6]. Djamali et al. have investigated the evolution
of graft function according to CKD stages [11], and they
observed a more rapid decline in graft function in early
stages (1T and 2T) than in late stages (3T and 4T). We
found a similar tendency in our study in the univariate
and multivariate analysis. These data demonstrated that
there is no increased rate of function loss at lower levels
of GFR and that grafts with GFR <30 mL/min/1.73 m
2
may be stabilized for long periods of time. As has been
stated [6], this is an important finding mainly in the current
era in which the percentage of older and suboptimal do-
nors in our country is very high and is still increasing,
and supports the utilization of grafts from old donors de-
spite worse eGFR when compared with younger donors.
Proteinuria, usually at low levels, is quite common after
kidney transplantation. It has been identified as a risk fac-
tor of poor graft survival [21,22]. After transplantation,
proteinuria may be due to various allograft pathologies
and/or may be a side effect of immunosuppression. How-
ever, no previous studies have evaluated its influence in the
Table 2. Association between selected variables and GFR at 12 months (intercept) and GFR slope (multivariate analysis)
Variable Coefficient ± ES tP
Variables affecting intercept
Recipient gender (male/female) −1.523 ± 0.394 −3.868 0.000
HCV status (negative/positive) −1.789 ± 0.567 −3.153 0.002
Donor age (years) −0.222 ± 0.012 −17.927 0.000
Delayed graft function −0.804 ± 0.412 −1.954 0.050
Acute rejection (no/yes) −2.179 ± 0.421 −5.179 0.000
eGFR at 3 months (mL/min/1.73 m
2) 0.604 ± 0.011 52.264 0.000
Proteinuria at 12 months (g/24 h) −0.438 ± 0.067 −6.516 0.000
Systolic blood pressure at 12 months (mmHg) −0.024 ± 0.010 −2.389 0.017
Variables affecting slope
Recipient gender by time −0.505 ± 0.103 −4.916 0.000
Time on dialysis (years) by time −0.201 ± 0.052 −3.871 0.000
HCV status (vs negative) by time −0.407 ± 0.136 −3.001 0.003
Primary renal disease (vs diabetes) by time
Chronic glomerulonephritis 1.051 ± 0.274 3.829 0.001
Interstitial nephritis 0.750 ± 0.324 2.314 0.000
Nephroangiosclerosis 1.028 ± 0.294 3.491 0.000
Polycystic disease 1.301 ± 0.293 4.442 0.000
Unknown/other 0.993 ± 0.276 3.596 0.000
eGFR at 3 months (mL/min/1.73 m2) by time −0.023 ± 0.003 −8.945 0.000
Proteinuria at 12 months (mg/day) by time −0.098 ± 0.018 −5.545 0.000
Immunosuppression 12 months (vs cyclosporine) by time
Tacrolimus 0.415 ± 0.193 2.147 0.032
No calcineurin inhibitors 0.874 ± 0.341 2.562 0.010
HCV , hepatitis C virus.
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uria at 12 months was one of the most important factors
negatively associated with graft function decline. These
findings strengthen the recommendations that antiprotei-
nuric measures should be applied liberally to transplant re-
cipients with proteinuria. As in other studies [6,7], female
recipients experienced a more rapid rate of decline, the rea-
son for which could be a higher sensitization. Recipient
HCV serology before transplant had a negative influence
in the decline of graft function. There are no data in pre-
vious studies about the effects of HCV infection on GFR
decline. The influence of HCV infection on graft survival
is controversial [23]. The impact of HCV status in the
slope could be explained by the increased incidence of
proteinuria and chronic allograft nephropathy in this pop-
ulation [24]. As in the general population, diabetes melli-
tus, as a primary renal disease, was associated with a
higher decline in graft function than all other diseases,
but two previous studies did not find this association in
renal transplant recipients [11,12].
CNI, cyclosporine and tacrolimus, are the most com-
monlyusedimmunosuppressiveagents;bothsharethesame
immunosuppressivemechanisms,andbotharenephrotoxic.
There are a few studies about the influence of immuno-
suppressive regimens in the decline of graft function. In a
registry study of 40 963 first kidney transplant recipients,
Gill et al. 2004 [8] observed a slower decline in GFR in
tacrolimus-treated patients and in patients who did not
receive CNI when compared with patients who received
cyclosporine microemulsion, and patients receiving my-
cophenolate mofetil also had a slower decline in GFR
than those who received azathioprine. Flechner et al. [25]
have emphasized the differences in GFR slopes between
sirolimus-based and cyclosporine-based immunosuppres-
sion in a randomized, prospective trial. Cyclosporine reci-
pients had a negative slope, while sirolimus recipients
had a positive slope. On examining the effects of im-
munosuppression on graft function, we also found that
cyclosporine-treated recipients had a more rapid decline
than tacrolimus-treated and CNI-free immunosuppression
recipients. This could support the belief that tacrolimus
displays lower toxicity than cyclosporine. However, con-
trol trials have shown no differences on patient and
graft survival [26] nor in the incidence of morphologic
characteristics consistent with chronic allograft nephrop-
athy [27] in recipients treated with tacrolimus when
compared with those on treatment with cyclosporine.
Patients on tacrolimus had a shorter follow-up than pa-
tients on cyclosporine and a different number of GFR
estimations that could influence the results.
Our study has some limitations as it is a retrospective
study, with significant differences in the length of follow-
up and consequently in the number of GFR measure-
ments. The assessment of graft function was performed
by the abbreviated MDRD equation which is one of the
methods of estimation of GFR recommended by K/DOQI
guidelines. However,thismethodofestimation ofGFRwas
considered to havea low precision and accuracy whencom-
pared with iothalamate GFR, and its slope underestimated
the rate of functional loss [10]. But more precise methods
of estimation of graft function are not always available,
and are more expensive and time consuming.
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